Dynavax (DVAX) shares were lower Monday after U.S. regulators rejected the company's application to market preventative hepatitis B vaccine Heplisav-B. The drugmaker also said it will need assistance from other pharmaceutical companies or financial partners to resubmit Heplisav-B for another shot at approval. In October, the U.S. Food and Drug Administration nixed a proposed advisory panel scheduled for November, which would have reviewed the Heplisav-B efficacy and safety data. The meeting cancellation initially prompted Dynavax investors to sell shares at that time amid concerns the FDA was leaning towards rejecting the application.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.